Linnaea Bio finds scientific work of the highest order that has waited, unnoticed, in the world's most serious laboratories — and carries it, with care, to the physicians and patients it was meant for.

Our lead program is a blood-based companion diagnostic for benign prostatic hyperplasia. The standard first-line drug class has been used for more than thirty years, yet works for only about one in three patients, and no test today can tell in advance who will respond. We are building that test — and the small, senior team that will take it through registration to the clinic.

林奈生物致力于从全球顶尖实验室中，发掘那些水平卓越却尚未得到充分重视的科学成果，并将其稳步转化，带到真正需要它的医生和患者身边。

我们的首个项目是良性前列腺增生的血液伴随诊断。一线标准药物已使用三十多年，却只对约三分之一的患者有效，而目前还没有任何检测能在用药前预判疗效。我们正在开发这项检测，并组建一支精干、资深的团队，推动它完成注册、走向临床。